Development of Nonsurfactant Cyclodextrin Nanoparticles Loaded With Anticancer Drug Paclitaxel

Panchagnula, 1998, Pharmaceutical aspects of paclitaxel, Int J Pharm, 172, 1, 10.1016/S0378-5173(98)00188-4 Blagosklonny, 1999, Molecular effects of paclitaxel: Myths and reality, Int J Cancer, 83, 151, 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5 Bitton, 1995, A preliminary risk-benefit assessment of paclitaxel, Drug Safety, 12, 196, 10.2165/00002018-199512030-00005 Spencer, 1994, Paclitaxel—A review of its pharmacudynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer, Drugs, 48, 794, 10.2165/00003495-199448050-00009 Rowinsky, 1993, Clinical pharmacology of taxol, Monogr Natl Cancer Inst, 15, 25 Onetka, 1993, Overview of taxol safety, Mongr Natl Cancer Inst, 15, 131 Dorr, 1994, Pharmacology and toxicology of Cremophor EL diluent, Ann Pharmacother, 28, S11, 10.1177/10600280940280S503 Weiss, 1990, Hypersensitivity reactions from taxol, J Clin Oncol, 8, 1263, 10.1200/JCO.1990.8.7.1263 Waugh, 1991, Stability, compatibility and plasticizer extraction of taxol (NSC-125973) injection diluted in infusion solutions and stored in various containers, Am J Hosp Pharm, 48, 1520 Gelderblom, 2001, Cremophor EL: The drawbacks and advantages of vehicle selection for drug formulation, Eur J Cancer, 37, 1590, 10.1016/S0959-8049(01)00171-X Lundberg, 1997, A submicron lipid emulsion coated with amphipathic polyethylene glycol for parenteral administration of paclitaxel (taxol), J Pharm Pharmacol, 49, 16, 10.1111/j.2042-7158.1997.tb06744.x Kan, 1999, Development of nonionic surfactant/phospholipids o/w emulsion as a paclitaxel delivery system, J Control Release, 58, 271, 10.1016/S0168-3659(98)00164-3 Sharma, 1994, Novel taxol formulations: Preparation and characterization of taxol containing liposomes, Pharm Res, 11, 889, 10.1023/A:1018994111594 Campbel, 2001, Influence of cationic lipids on the stability and membrane properties of paclitaxel-containing liposomes, J Pharm Sci, 90, 1091, 10.1002/jps.1063 Fonseca, 2002, Paclitaxel-loaded PLGA nanoparticles, preparation, physicochemical characterization and in vitro antitumoral activity, J Control Release, 83, 273, 10.1016/S0168-3659(02)00212-2 Kim, 2003, Toxic characteristics of methoxy polyethyleneglycol/poly epsilon caprolactone nanospheres: In vitro and in vivo studies in the normal mice, Biomaterials, 24, 55, 10.1016/S0142-9612(02)00248-X Mitra, 2003, Effect of surfactant on fabrication and characterization of paclitaxel-loaded polybutylcyanoacrylate nanoparticulate delivery systems, J Pharm Pharmacol, 55, 895, 10.1211/0022357021341 Mu, 2003, A novel controlled release formulation for the anticancer drug paclitaxel (taxol): PLGA nanoparticles containing Vitamin A TPGS, J Control Release, 86, 33, 10.1016/S0168-3659(02)00320-6 Potineni, 2003, Polyethylene oxide modified poly beta-amino ester nanoparticles as a pH-sensitive biodegradable system for paclitaxel delivery, J Control Release, 86, 223, 10.1016/S0168-3659(02)00374-7 Suh, 1998, Regulation of smooth muscle cell proliferation using paclitaxel-loaded poly(ethylene oxide)-poly(lactide/glycolide) nanospheres, J Biomed Mater Res, 42, 331, 10.1002/(SICI)1097-4636(199811)42:2<331::AID-JBM19>3.0.CO;2-L Pendri, 1998, Antitumor activity of paclitaxel-2′-glycinate conjugated to polyethylene glycol: A water soluble drug, Anticancer Drug Des, 13, 387 Rodrigues, 1995, Synthesis and β-lactamase mediated activation of cephalosporin-taxol prodrug, Chem Biol, 2, 223, 10.1016/1074-5521(95)90272-4 Safovy, 2003, Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug drug delivery, Bioconjug Chem, 14, 302, 10.1021/bc020033z Sharma, 1995, Pharmaceutical and physical properties of paclitaxel (taxol) complexes with cyclodextrins, J Pharm Sci, 84, 1223, 10.1002/jps.2600841015 Cserhati, 1994, Interaction of taxol and other anticancer drugs with hydroxypropyl-β-cyclodextrin, Int J Pharm, 108, 69, 10.1016/0378-5173(94)90417-0 Cserhati, 1995, Interaciton of taxol and other anticancer drugs with α-cyclodextrin, J Pharm Biomed Anal, 13, 533, 10.1016/0731-7085(95)01263-K Dordunoo, 1996, Solubility and stability of taxol: Effects of buffers and cyclodextrins, Int J Pharm, 133, 191, 10.1016/0378-5173(96)04443-2 Alcaro, 2002, Preparation, characterization, molecular modeling and in vitro activity of paclitaxel-cyclodextrin complexes, Bioorg Med Chem Lett, 12, 1637, 10.1016/S0960-894X(02)00217-2 Sparreboom, 2005, Comparative, preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitacel (ABI-007) and paclitaxel formulated in cremophor (taxol), Clin Cancer Res, 11, 4136, 10.1158/1078-0432.CCR-04-2291 Micha, 2006, Abraxane in the treatment of ovarian cancer: The absence of hypersensivity reactions, Gynecol Oncol, 100, 437, 10.1016/j.ygyno.2005.09.012 Couvreur, 1980, Tissue distribution of antitumor drugs associated with polyalkylcyanoacrylate nanoparticles, J Pharm Sci, 69, 199, 10.1002/jps.2600690222 Rolland, 1989, Clinical pharmacokinetics of doxorubicin in hepatoma patients after a single intravenous injection of free and nanoparticle-bound anthracyclin, Int J Pharm, 54, 113, 10.1016/0378-5173(89)90330-X Bennis, 1994, Enhanced cytotoxicity of doxorubicin encapsulated in polyisohexylcyanoacrylate nanospheres against multidrug resistant cell culture, Eur J Cancer, 30A, 89, 10.1016/S0959-8049(05)80025-5 Rowinsky, 1995, Drug therapy: Paclitaxel-review article, N Engl J Med, 332, 1004, 10.1056/NEJM199504133321507 Memisoglu, 2002, Amphiphilic β-cyclodextrins modified on the primary face: Synthesis, characterization and evaluation of their potential as novel excipients in the preparation of nanocapsules, J Pharm Sci, 91, 1214, 10.1002/jps.10105 Memisoglu-Bilensoy, 2006, Amphiphilic cyclodextrins and microencapsulation Duchene, 1999, Cyclodextrins and carrier systems, J Control Release, 62, 263, 10.1016/S0168-3659(99)00046-2 Memisoglu, 2003, Non-surfactant nanospheres of progesterone inclusion complexes with amphiphilic β-cyclodextrins, Int J Pharm, 251, 143, 10.1016/S0378-5173(02)00593-8 Memisoglu, 2003, Direct formation of nanospheres from amphiphilic β-cyclodextrin inclusion complexes, Pharm Res, 20, 117, 10.1023/A:1022263111961 Memisoglu-Bilensoy, 2005, Tamoxifen citrate loaded amphiphilic cyclodextrin nanoparticles: In vitro characterization and cytotoxicity, J Control Release, 104, 489, 10.1016/j.jconrel.2005.03.006 Fessi H, Devissaguet JP, Puisieux F, Thies C. 1992. Process for the preparation of dispersible colloidal systems of a substance in the form of nanoparticles. US Patent No 5,118,528. Hedges, 1991, Complexation in modified cyclodextrins compared with unmodified cyclodextrins Thompson, 1997, Cyclodextrins as enabling excipients: Their present and future use in pharmaceuticals, CRC Crit Ther Drug Carrier Syst, 14, 1 Kawashima, 1982, Spherical crystallization: Direct spherical agglomerization of salicylic acid crystals during crystallization, Science, 216, 1127, 10.1126/science.216.4550.1127 Legrand, 1999, Polymeric nanocapsules as drug delivery systems: A review, STP Pharma Sci, 9, 411 Brannon-Peppas, 2004, Nanoparticles and targeted systems for cancer therapy, Adv Drug Deliv Rev, 56, 1649, 10.1016/j.addr.2004.02.014 Memisoglu-Bilensoy, 2006, Effect of drug physicochemical properties on in vitro characteristics of amphiphilic cyclodextrin nanospheres and nanocapsules, J Microencapsul, 23, 59, 10.1080/02652040500286227